About: Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses
Creator	Berkhout, Ben Haasnoot, Joost
source	Medline; PMC
abstract	For almost three decades, researchers have studied the possibility to use nucleic acids as antiviral therapeutics. In theory, compounds such as antisense oligonucleotides, ribozymes, DNAzymes, and aptamers can be designed to trigger the sequence-specific inhibition of particular mRNA transcripts, including viral genomes. However, difficulties with their efficiency, off-target effects, toxicity, delivery, and stability halted the development of nucleic acid-based therapeutics that can be used in the clinic. So far, only a single antisense drug, Vitravene for the treatment of CMV-induced retinitis in AIDS patients, has made it to the clinic. Since the discovery of RNA interference (RNAi), there is a renewed interest in the development of nucleic acid-based therapeutics. Antiviral RNAi approaches are highly effective in vitro and in animal models and are currently being tested in clinical trials. Here we give an overview of antiviral nucleic acid-based therapeutics. We focus on antisense and RNAi-based compounds that have been shown to be effective in animal model systems.
has issue date	2009-01-01(xsd:dateTime)
bibo:doi	10.1007/978-3-540-79086-0_9
bibo:pmid	19048203
has license	no-cc
sha1sum (hex)	05d2c354ee8ab0a66de7b548e19b8c5458545770
schema:url	https://doi.org/10.1007/978-3-540-79086-0_9
resource representing a document's title	Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses
has PubMed Central identifier	PMC7119910
has PubMed identifier	19048203
schema:publication	Antiviral Strategies
resource representing a document's body	covid:05d2c354ee8ab0a66de7b548e19b8c5458545770#body_text
is schema:about of	named entity 'BASED' named entity 'PATHOGENIC' named entity 'BATTLE' named entity 'VIRUSES' named entity 'NUCLEIC ACIDS' named entity 'THERAPEUTICS' named entity 'Nucleic Acids' named entity 'ribozymes' named entity 'RNAi' named entity 'therapeutic strategies' named entity 'methylene bridge' named entity 'liver' named entity 'clinical trials' named entity 'CD34' named entity 'siRNAs' named entity 'ribozymes' named entity 'siRNA' named entity 'chronic infection' named entity 'mammalian cells' named entity 'HIV-1' named entity 'nucleotide' named entity 'sugar' named entity 'siRNAs' named entity 'ribozyme' named entity 'Ebola virus' named entity 'Chapter 11' named entity 'ribozymes' named entity 'HIV-1' named entity 'HCV' named entity 'ribozymes' named entity 'mice' named entity 'siRNA' named entity 'exogenous' named entity 'transduced' named entity 'mRNAs' named entity 'substrates' named entity 'Ligands' named entity 'highly active antiretroviral therapy' named entity 'aptamers' named entity 'antisense strand' named entity 'therapeutic effects' named entity 'siRNAs' named entity 'nuclease' named entity 'Virus' named entity 'siRNA' named entity 'cell lines' named entity 'cofactors' named entity 'shRNAs' named entity 'protein' named entity 'infection' named entity 'hematopoietic progenitor cells' named entity 'T-lymphocytes' named entity 'intracellular' named entity 'cytomegalovirus' named entity 'knock-down' named entity 'cell surface receptors' named entity 'viruses' named entity 'Vitravene' named entity 'nucleic acid' named entity 'nucleotides' named entity 'RNAi' named entity 'Dicer' named entity 'host cell' named entity 'toxicity' named entity 'miRNA' named entity 'PNA' named entity 'siRNAs' named entity 'virus' named entity 'aptamers' named entity 'shRNAs' named entity 'RNAi' named entity 'gene therapy' named entity 'antisense technology' named entity 'siRNAs' named entity 'viral RNA' named entity 'siRNAs' named entity 'knock-down' named entity 'knock-down' named entity 'Zamecnik' named entity 'health problem'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software